<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03034382</url>
  </required_header>
  <id_info>
    <org_study_id>SH1</org_study_id>
    <nct_id>NCT03034382</nct_id>
  </id_info>
  <brief_title>Morphine and/or Nalbuphine as Adjuvants in Ultrasound Guided Interscalene Block: for Shoulder Surgeries</brief_title>
  <official_title>Adjuvants to Ultrasonic Guided Interscalene Block In Arthroscopic Rotator Cuff Repair; Morphine and/or Nalbuphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <brief_summary>
    <textblock>
      the aim of this study is to evaluate the duration of analgesia when either morphine or
      nalbuphine or both are used as adjuvants in sonar guided interscalene brachial plexus block
      for arthroscopic rotator cuff repair.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the total number of analgesic requests</measure>
    <time_frame>72 hours postoperative followup</time_frame>
    <description>the combination of opioid agonist and mixed agonist-antagonist peripherally prevents the development of early tolerance of the opioid agonist; thus the agonist would maintain the same efficacy and this will be obvious clinically by a reduction in the requests for supplementary analgesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of analgesia</measure>
    <time_frame>72 hours followup</time_frame>
    <description>duration of analgesia when morphine or nalbuphine or both used in interscalene block using VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>72 hours followup</time_frame>
    <description>- The patient satisfaction score. Patients were also asked to rate their satisfaction with the analgesia on a scale of 0-10 (0 for total dissatisfaction to 10 for total satisfaction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The first time to ask for analgesics</measure>
    <time_frame>72 hours followup</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedation score</measure>
    <time_frame>72 hours followup</time_frame>
    <description>recorded every 4 hours; ranging from alert, drowsy, sleeping but responsive to verbal commands up to unarousable (we consider sedation score 3 or more as clinically significant sedation that mandate close patient observation every hour).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of vomiting attacks</measure>
    <time_frame>72 hours followup</time_frame>
    <description>recorded every 4 hours. A vomiting attack was defined by events of vomiting that occurred in a rapid sequence (&lt;1 minute between events). If vomiting was separated by more than 1 minute; they will be considered to be separate attacks. Retching (the same as vomiting but without expulsion of gastric contents) was considered as vomiting. If the patient experienced vomiting; ondansetron 4 mg IV was given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>itching</measure>
    <time_frame>72 hours followup</time_frame>
    <description>Itching is assessed using an ordinal scale (0 = no itch, 1 = mild, 2 = moderate, 3 = severe).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rotator Cuff Tear</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg morphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nalbuphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg nalbuphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine and Nalbuphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
combination of 5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine 0.5%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 ml of lidocaine 1% and epinephrine 1:400,000 and 5 ml of Bupivacaine 0.5% in interscalene block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block</description>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>Morphine and Nalbuphine</arm_group_label>
    <other_name>morphine sulphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine</intervention_name>
    <description>5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block</description>
    <arm_group_label>Nalbuphine</arm_group_label>
    <arm_group_label>Morphine and Nalbuphine</arm_group_label>
    <other_name>nubain</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0.5%</intervention_name>
    <description>10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block</description>
    <arm_group_label>Bupivacaine 0.5%</arm_group_label>
    <other_name>Marcaine HCL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Hydrochloride 1% and epinephrine 1:400,000</intervention_name>
    <description>10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block</description>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>Nalbuphine</arm_group_label>
    <arm_group_label>Morphine and Nalbuphine</arm_group_label>
    <arm_group_label>Bupivacaine 0.5%</arm_group_label>
    <other_name>lidocaine HCL and Adrenaline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for arthroscopic repair of rotator cuff muscle tear of the
             shoulder.

          -  ASA physical status I - ле.

        Exclusion Criteria:

          -  Infection at the site of injection.

          -  Coagulopathy or other bleeding diathesis.

          -  Known allergy to drugs in the study

          -  Preexisting neurologic deficits in the area to be blocked.

          -  Inability to communicate with the investigator and the hospital staff.

          -  History of chronic opioid use.

          -  Morbid obesity BMI&gt;40.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud A Aly, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kawser H Mohammed, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman A Mamdouh, Ass Prof</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimaa A Husien, Msc</last_name>
    <phone>01002953253</phone>
    <phone_ext>002</phone_ext>
    <email>shimo.9feb@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut University Hospitals</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman A Mamdouh, AssProf</last_name>
      <phone>01066066001</phone>
      <phone_ext>002</phone_ext>
      <email>aymanosman2000@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Shimaa Abbas Hassan</investigator_full_name>
    <investigator_title>Primary investigator</investigator_title>
  </responsible_party>
  <keyword>morphine</keyword>
  <keyword>nalbuphine</keyword>
  <keyword>arthroscopic rotator cuff repair</keyword>
  <keyword>ultrasound guided interscalene block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

